Trial Profile
A Phase I, Single-Sequence, Placebo-Controlled, Single-Blind Study to Evaluate the Effect of Repeat Oral Dosing of GSK1120212 on Cardiac Repolarization in Subjects With Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Trametinib (Primary)
- Indications Solid tumours
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 03 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2013 Actual initiation date changed from Sep 2011 to Sep 2012 as reported by ClinicalTrials.gov.
- 31 May 2013 Actual initiation date changed from Sep 2012 to Sep 2011 as reported by ClinicalTrials.gov.